| US 7,341,552 B2 | ||
| Gene sets for glioma classification | ||
| Wei Zhang, Houston, Tex. (US); Greg Fuller, Houston, Tex. (US); Ed Dougherty, College Station, Tex. (US); and Kenneth Hess, Houston, Tex. (US) | ||
| Assigned to The University of Texas System Board of Regents, Austin, Tex. (US); and The Texas A & M University System, College Station, Tex. (US) | ||
| Filed on Mar. 17, 2003, as Appl. No. 10/390,343. | ||
| Claims priority of provisional application 60/364608, filed on Mar. 15, 2002. | ||
| Prior Publication US 2004/0053277 A1, Mar. 18, 2004 | ||
| Int. Cl. C40B 30/00 (2006.01) | ||
| U.S. Cl. 506—7 [435/6] | 19 Claims |
| 1. A method of classifying a glioma comprising:
(a) obtaining a primary glioma tumor sample;
(b) measuring in cells of the tumor sample the mRNA or protein expression level of MAPKK1, HTF4, transducin β2, BMP2A, TrkB,
DAP3, RAB3A, transcription elongation factor SII, integrin beta I, IGFBP2, NKEFB, HSP27, neuromodulin, and LIMK1;
(c) comparing the mRNA or protein expression levels obtained in step (b) with the expression levels of the mRNAs or proteins
in step (b) from at least a first known glioma cell type; and
(d) classifying said tumor sample as glioblastome multiforme (GM) when the sample shows altered expression of IGFBP2, NKEPFB
and one or more of HSP27, neuromodulin or LIMK1, anaplastic astrocytoma (AA) when the sample shows altered expression of MAPKK1
and one or both of BMP2A or HTF4, anaplastic oligodendroglioma (AO) when the sample shows altered expression of DAP3 and either
TrkB and RAB3A, or transcription elongation factor II and integrin β1, or oligodendroglioma (OL) when the sample shows altered
expression of transducin β2 based on the expression comparison in step (c).
|